Clinical trial
Efficacy of Sequential Therapies After Osteoanabolic Treatment in Postmenopausal Women With Severe Osteoporosis: the Sequential Treatment After Romosozumab and Teriparatide/Abaloparatide (START) Study
NCT06164795 is registered in ClinicalTrials.gov with 424 General Military Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy of Sequential Therapies After Osteoanabolic Treatment in Postmenopausal Women With Severe Osteoporosis: the Sequential Treatment After Romosozumab and Teriparatide/Abaloparatide (START) Study
- Lead sponsor
- 424 General Military Hospital
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- November 25, 2023
- Completion date
- December 31, 2027
- Enrollment
- 150 (estimated)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.